Top

Cancer Chemotherapy and Pharmacology

Published in:

01-06-2019 | Original Article

Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique

Authors: Kotaro Kimura, Keishi Yamasaki, Koji Nishi, Kazuaki Taguchi, Masaki Otagiri

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2019

Abstract

Purpose

Nanoparticles of human serum albumin (HSA) prepared using a desolvation method possess sizes suitable for tumor accumulation. Here, we report on an investigation of the anti-tumor effects and biodistribution of doxorubicin–HSA nanoparticles in vitro and in vivo.

Methods

The cytotoxicity of nanoparticles was evaluated in 2D and 3D colon 26 cell cultures. Furthermore, the biodistribution and the anti-tumor activity of nanoparticles in colon 26-bearing mice were investigated. Assessments on the effect on metastasis and the toxicity were also carried out.

Results

Doxorubicin–HSA nanoparticles showed cytotoxicity in colon 26 cancer cell cultures, although the cytotoxicity was less in the case of nanoparticles than in free doxorubicin. In vivo anti-tumor activity was more pronounced in nanoparticles despite the fact that their accumulation in tumors was not superior to that of free doxorubicin, suggesting that factors other than accumulation contribute to the enhanced anti-tumor activity of these nanoparticles. The administration of nanoparticles also resulted in the suppression of metastasis.

Conclusions

The prepared nanoparticles appear to be effective for cancer therapy although further studies will be needed to clarify the details of anti-tumor activity and the toxicity of these nanoparticles.

Hobbs SK, Monsky WL, Yuan F et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607–4612CrossRef

Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol Semin Orig Investig 26:57–64. https://doi.org/10.1016/j.urolonc.2007.03.015 CrossRef

Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71–79. https://doi.org/10.1016/j.addr.2012.10.002 CrossRefPubMed

Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36–48. https://doi.org/10.1016/j.addr.2012.09.037 CrossRefPubMed

Quader S, Kataoka K (2017) Nanomaterial-enabled cancer therapy. Mol Ther 25:1501–1513. https://doi.org/10.1016/j.ymthe.2017.04.026 CrossRefPubMedPubMedCentral

Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157:168–182. https://doi.org/10.1016/j.jconrel.2011.07.031 CrossRefPubMed

Elzoghby AO (2013) Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release 172:1075–1091. https://doi.org/10.1016/j.jconrel.2013.09.019 CrossRefPubMed

Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–183. https://doi.org/10.1016/j.jconrel.2008.05.010 CrossRefPubMed

Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:876–885. https://doi.org/10.1016/j.addr.2007.08.044 CrossRefPubMed

10.

Otagiri M, Chuang VTG (2016) Albumin in medicine: pathological and clinical applications. Springer, SingaporeCrossRef

11.

Langer K, Balthasar S, Vogel V et al (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257:169–180CrossRef

12.

Langer K, Anhorn MG, Steinhauser I et al (2008) Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 347:109–117. https://doi.org/10.1016/j.ijpharm.2007.06.028 CrossRefPubMed

13.

Storp B, Engel A, Boeker A et al (2012) Albumin nanoparticles with predictable size by desolvation procedure. J Microencapsul 29:138–146. https://doi.org/10.3109/02652048.2011.635218 CrossRefPubMed

14.

Kimura K, Yamasaki K, Nakamura H et al (2018) Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives. Chem Pharm Bull (Tokyo) 66:382–390. https://doi.org/10.1248/cpb.c17-00838 CrossRef

15.

Dreis S, Rothweiler F, Michaelis M et al (2007) Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 341:207–214. https://doi.org/10.1016/j.ijpharm.2007.03.036 CrossRefPubMed

16.

Miao FQ, An YL, Yang R et al (2014) Preparation of DOX/BSANP and its antitumor effect on bel-7404 liver cancer cells in vitro and in vivo. Biomed Mater Eng 24:599–607. https://doi.org/10.3233/bme-130847 CrossRefPubMed

17.

Merodio M, Arnedo A, Renedo MJ, Irache JM (2001) Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci 12:251–259CrossRef

18.

Sripriyalakshmi S, Anjali CH, George PD et al (2014) BSA nanoparticle loaded atorvastatin calcium–a new facet for an old drug. PLoS One 9:e86317. https://doi.org/10.1371/journal.pone.0086317 CrossRefPubMed

19.

Wilson B, Lavanya Y, Priyadarshini SR et al (2014) Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharm 473:73–79. https://doi.org/10.1016/j.ijpharm.2014.05.056 CrossRefPubMed

20.

Jose P, Sundar K, Anjali CH, Ravindran A (2015) Metformin-loaded BSA nanoparticles in cancer therapy: a new perspective for an old antidiabetic drug. Cell Biochem Biophys 71:627–636. https://doi.org/10.1007/s12013-014-0242-8 CrossRefPubMed

21.

Satya Prakash S (2010) Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomed. https://doi.org/10.2147/ijn.s10443 CrossRef

22.

Wang Z, Li J, Cho J, Malik AB (2014) Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nat Nanotechnol 9:204–210. https://doi.org/10.1038/nnano.2014.17 CrossRefPubMedPubMedCentral

23.

Galisteo-Gonzalez F, Molina-Bolivar JA (2014) Systematic study on the preparation of BSA nanoparticles. Colloids Surf B Biointerfaces 123:286–292. https://doi.org/10.1016/j.colsurfb.2014.09.028 CrossRefPubMed

24.

Chen RF (1967) Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 242:173–181PubMed

25.

Suzuki I, Iigo M, Ishikawa C et al (1997) Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities. Int J Cancer 73:607–612CrossRef

26.

Elsadek B, Kratz F (2012) Impact of albumin on drug delivery-new applications on the horizon. J Control Release 157:4–28. https://doi.org/10.1016/j.jconrel.2011.09.069 CrossRefPubMed

27.

Kratz F, Elsadek B (2012) Clinical impact of serum proteins on drug delivery. J Control Release 161:429–445. https://doi.org/10.1016/j.jconrel.2011.11.028 CrossRefPubMed

28.

Steiniger SC, Kreuter J, Khalansky AS et al (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759–767. https://doi.org/10.1002/ijc.20048 CrossRefPubMed

29.

Li H, Hummon AB (2011) Imaging mass spectrometry of three-dimensional cell culture systems. Anal Chem 83:8794–8801. https://doi.org/10.1021/ac202356g CrossRefPubMed

30.

Liu X, Weaver EM, Hummon AB (2013) Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry. Anal Chem 85:6295–6302. https://doi.org/10.1021/ac400519c CrossRefPubMedPubMedCentral

31.

Goodman TT, Chee PN, Suzie HP (2008) 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. Bioconjug Chem 19:1951–1959. https://doi.org/10.1021/bc800233a CrossRefPubMedPubMedCentral

32.

Khaitan D, Dwarakanath BS (2006) Multicellular spheroids as an in vitro model in experimental oncology: applications in translational medicine. Expert Opin Drug Discov 1:663–675. https://doi.org/10.1517/17460441.1.7.663 CrossRefPubMed

33.

Mehta G, Hsiao AY, Ingram M et al (2012) Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release 164:192–204. https://doi.org/10.1016/j.jconrel.2012.04.045 CrossRefPubMedPubMedCentral

34.

Perche F, Patel NR, Torchilin VP (2012) Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release 164:95–102. https://doi.org/10.1016/j.jconrel.2012.09.003 CrossRefPubMedPubMedCentral

35.

Polyak A, Palade EA, Balogh L et al (2011) In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles. Nucl Med Rev Cent East Eur 14:55–62CrossRef

36.

Ponta A, Bae Y (2014) Tumor-preferential sustained drug release enhances antitumor activity of block copolymer micelles. J Drug Target 22:619–628. https://doi.org/10.3109/1061186X.2014.910793 CrossRefPubMed

37.

Soma CE, Dubernet C, Barratt G et al (2000) Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J Control Release 68:283–289CrossRef

38.

Tsukigawa K, Liao L, Nakamura H et al (2015) Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin. Cancer Sci 106:270–278. https://doi.org/10.1111/cas.12592 CrossRefPubMedPubMedCentral

39.

Kinoshita R, Ishima Y, Ikeda M et al (2015) S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes. J Control Release 217:1–9. https://doi.org/10.1016/j.jconrel.2015.08.036 CrossRefPubMed

40.

Renu K, Abilash VG, Pb TP, Arunachalam S (2018) Molecular mechanism of doxorubicin-induced cardiomyopathy—an update. Eur J Pharmacol 818:241–253. https://doi.org/10.1016/j.ejphar.2017.10.043 CrossRefPubMed

41.

Cagel M, Bernabeu E, Moretton MA, Chiappetta DA (2017) Doxorubicin : nanotechnological overviews from bench to bedside. https://doi.org/10.1016/j.drudis.2016.11.005 CrossRef

42.

Pereverzeva E, Treschalin I, Bodyagin D et al (2007) Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity. Int J Pharm 337:346–356. https://doi.org/10.1016/j.ijpharm.2007.01.031 CrossRefPubMed

43.

Fahrlander E, Schelhaas S, Jacobs AH, Langer K (2015) PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent. Nanotechnology 26:145103. https://doi.org/10.1088/0957-4484/26/14/145103 CrossRefPubMed

Title: Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique
Authors: Kotaro Kimura
Keishi Yamasaki
Koji Nishi
Kazuaki Taguchi
Masaki Otagiri
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03832-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2019

Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability

The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model

d,l-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro

Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling

LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer